End-stage, age-related macular degeneration (AMD) is the leading cause of irreversible vision loss and legal blindness in people over 65. A new FDA-approved, implantable miniature telescopic lens is now available through a treatment program that has partnered with Rush University Medical Center and the Chicago Lighthouse.
This comprehensive treatment program has been designed by CentraSight, the only treatment program available in the United States that uses an FDA-approved implantable telescopic lens. This multidisciplinary team will be led by a retina specialist from Rush and will provide patient candidacy assessment, visual training and rehabilitation.
The CentraSight treatment program involves four steps, which include:
- Diagnosis of end-stage AMD by a Rush retina physician
- Presurgery training by low-vision specialists at the Chicago Lighthouse
- Implantation surgery at Rush University Medical Center
- Rehabilitation, which will be performed at the Chicago Lighthouse.
If you are interested in finding out if you are a candidate for the telescopic lens, please call (877) 997-4448 between 10 a.m. and 8 p.m. CT to speak with a case manager.